Mineralys Therapeutics develops lorundrostat, an oral medicine for high blood pressure that is hard to control with other treatments. It last closed at $13.66 on Nov 20, down 3.53% on the day. The next earnings report for MLYS is expected around Thu, Mar 11, 2027, after the close. For the quarter ended Sep 2026, MLYS reported EPS of -$0.64. Over its last 8 reports the stock moved an average of 4.3% the session after earnings. Over the last 12 months MLYS insiders bought $8.8M of stock on the open market and sold $71.3M, according to SEC Form 4 filings.
AI Auto Pilots
Is MLYS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold MLYS.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on MLYSStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
MLYS · as of the Nov 20 close · updated each morning
Downtrend, oversold
The stock is 21% below its 20 day and 55% below its 50 day average. It is 88% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 29), oversold. The nearest support is the 52 week low at $13.57, and the nearest resistance the Pivot at $14.01.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 9.2%/day
Key levels
$44.9952 week high+229.4%
$25.75200 day average+88.5%
$24.18100 day average+77.0%
$21.1250 day average+54.6%
$16.88Swing high (Nov 12)+23.6%
$16.5320 day average+21.0%
$14.44Pivot R1+5.7%
$14.01Pivot+2.6%
$13.66Last close
$13.5752 week low−0.7%
$13.22Pivot S1−3.2%
Indicators
RSI (14)
28.67
Oversold below 30
Oversold
MACD
-2.06
Below its signal line
Bearish
Stochastic
4.2
Near the bottom of its range
Oversold
ADX (14)
26.7
Trending down
Williams %R
-97.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-89.1
Oversold below −100, overbought above 100
Neutral
Rate of change
−10.9%
Change over 10 sessions
Bearish
ATR (14)
$1.26
Typical daily range, 9.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling, oversold
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchOversold
VolatilityNormal, 22.9%/day
Key levels
$44.9952 week high+229.4%
$25.75200 day average+88.5%
$24.18100 day average+77.0%
$21.1250 day average+54.6%
$16.88Swing high (Nov 12)+23.6%
$16.5320 day average+21.0%
$14.44Pivot R1+5.7%
$14.01Pivot+2.6%
$13.66Last close
$13.5752 week low−0.7%
$13.22Pivot S1−3.2%
Indicators
RSI (14)
24.83
Oversold below 30
Oversold
MACD
-3.17
Below its signal line
Bearish
Stochastic
2.0
Near the bottom of its range
Oversold
ADX (14)
17.7
No clear trend
Williams %R
-99.5
Oversold below −80, overbought above −20
Oversold
CCI (20)
-172.6
Oversold below −100, overbought above 100
Oversold
Rate of change
−51.6%
Change over 10 sessions
Bearish
ATR (14)
$3.13
Typical daily range, 22.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for MLYS
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how MLYS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow MLYS usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for MLYSHow many large options trades hit MLYS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in MLYS in the last 90 days.
From SEC Form 4 filings by MLYS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MLYS is in one of them and how their past MLYS trades turned out.
Mineralys Therapeutics is a biopharmaceutical company based in Radnor, Pennsylvania, that develops medicines for diseases driven by high levels of aldosterone, a hormone that affects blood pressure. Its main product candidate, lorundrostat, is a pill taken by mouth that is being developed to treat high blood pressure, especially cases that do not respond fully to other treatments. The company is also studying lorundrostat in patients with chronic kidney disease and obstructive sleep apnea. Its target patients are adults with high blood pressure, and the company has not yet sold a product.